Fintel reports that on December 22, 2023, Mizuho initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy recommendation.
Analyst Price Forecast Suggests 70.08% Upside
As of December 16, 2023, the average one-year price target for Syndax Pharmaceuticals is 35.62. The forecasts range from a low of 28.28 to a high of $45.15. The average price target represents an increase of 70.08% from its latest reported closing price of 20.94.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Syndax Pharmaceuticals is 14MM, a decrease of 89.24%. The projected annual non-GAAP EPS is -2.58.
What is the Fund Sentiment?
There are 392 funds or institutions reporting positions in Syndax Pharmaceuticals. This is an increase of 16 owner(s) or 4.26% in the last quarter. Average portfolio weight of all funds dedicated to SNDX is 0.19%, a decrease of 21.24%. Total shares owned by institutions increased in the last three months by 0.90% to 76,406K shares. The put/call ratio of SNDX is 0.75, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 7,642K shares representing 9.01% ownership of the company. In it’s prior filing, the firm reported owning 7,444K shares, representing an increase of 2.59%. The firm decreased its portfolio allocation in SNDX by 24.66% over the last quarter.
Kynam Capital Management holds 3,600K shares representing 4.24% ownership of the company. In it’s prior filing, the firm reported owning 3,262K shares, representing an increase of 9.39%. The firm decreased its portfolio allocation in SNDX by 8.95% over the last quarter.
VGHCX – Vanguard Health Care Fund Investor Shares holds 3,092K shares representing 3.65% ownership of the company. No change in the last quarter.
Avidity Partners Management holds 2,821K shares representing 3.33% ownership of the company. In it’s prior filing, the firm reported owning 2,872K shares, representing a decrease of 1.81%. The firm decreased its portfolio allocation in SNDX by 21.43% over the last quarter.
PFM Health Sciences holds 2,715K shares representing 3.20% ownership of the company. In it’s prior filing, the firm reported owning 2,172K shares, representing an increase of 19.99%. The firm increased its portfolio allocation in SNDX by 5.01% over the last quarter.
Syndax Pharmaceuticals Background Information
(This description is provided by the company.)
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.